passages.id: split_8_test_435_passage
passages.type: progene_text
passages.text: Three new aromatase inhibitors have recently completed phase III evaluation as treatment of metastatic breast cancer in post - menopausal women whose disease has progressed despite tamoxifen therapy : anastrozole ( ARIMIDEX , Zeneca ) , letrozole ( FEMARA , Novartis ) and vorozole ( RIVIZOR , Janssen ) .